SMEP
17.1.2024 10:57:28 CET | Business Wire | Press release
Saudi Arabia reinforced its call for an immediate ceasefire in Gaza, and an end to the spiraling volatility in the Red Sea, today at the World Economic Forum (WEF) Annual Meeting 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116473725/en/
Saudi Arabia reiterates call for immediate ceasefire in Gaza at the World Economic Forum Annual Meeting 2024 (Photo: AETOSWire)
Speaking at a session on ‘Securing an Insecure World’, Saudi Arabia’s Minister of Foreign Affairs, His Highness Prince Faisal bin Farhan bin Abdullah, said: “We need to focus on the immediate crisis which is the suffering that is happening in Gaza.
“The international community has been moving more in the direction that we have called for since the beginning, which is a ceasefire and more humanitarian aid. But we need to do more. We agree that regional peace includes peace for Israel, but that can only happen through peace for the Palestinians, through a Palestinian state.”
On the escalating volatility in the Red Sea, His Highness added: “Freedom of navigation in the Red Sea is something that impacts all of us, and the priority needs to be de-escalation.”
During a panel session on “Frictionless Services”, His Excellency Dr. Majid A. Alkassabi, Minister of Commerce, described the speed and scale of Saudi Arabia’s economic diversification, saying The Kingdom “has revamped over 200 laws and bylaws to make the business environment attractive.”
His Excellency Adel A. Aljubeir, Minister of State for Foreign Affairs, Member of the Council of Ministers, and Envoy for Climate, Member of the Council of Ministers and Envoy for Climate Affairs reiterated the need for substantive global collaboration to tackle the climate crisis, saying, “unless we work together, we are going to achieve nothing,” in a session as part of the new Saudi House: Bold Visions Series – the Kingdom’s pavilion connecting policymakers and innovators.
In ‘Gulf Economies: All In,’ His Excellency Khalid A. Al Falih, Minister of Investment, shared his optimistic outlook for the Gulf, noting how “the GCC is attracting FDI at more than twice the average rate than around the world when you compare it and normalize it for GDP. We believe we are at inflection point of increase of FDI, as we have seen in Saudi Arabia.”
In a session on ‘Regulating Non-Banks’, His Excellency Mohammed Aljadaan, Minister of Finance, warned governments not to “kill innovation” and deprive the private sector from investment opportunities by applying blanket regulatory frameworks to banks and non-regulated financial institutions, alike.
In a session on ‘AI: The Great Equaliser’, His Excellency Abdullah A. Alswaha, Minister of Communications and Information Technology, said the Kingdom’s consistency on being “pro-innovation, pro-partnership” has harnessed emerging technologies like Generative AI to build a human-centric future.
His Excellency Bandar I. Alkhorayef, Minister of Industry and Mineral Resources, highlighted Saudi Arabia’s “three dimensional” policy approach to building industrial capabilities and creating an investor-friendly environment to unlock the untapped potential of Saudi Arabia’s vast mineral assets.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116473725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom